An interventional study of BIOMONITOR IV with study software in Heart Failure, Arrhythmia and Decompensated Heart Failure, sponsored by Biotronik SE & Co. KG. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by Biotronik SE & Co. KG · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Heart Failure by Biotronik SE & Co. KG — 3 open to participants now, 6 under way, none of them phase 3. Heart Failure · Biotronik SE & Co. KG.
Among the 45 studies in Heart Failure by Biotronik SE & Co. KG, this one is the 9th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2025, is one of 17 with no phase, and was the 43rd registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →3 of the 45 studies in Heart Failure by Biotronik SE & Co. KG are open now, in 12 countries. Recruiting first, the newest first:
Biotronik SE & Co. KG · Sites in Austria, Czechia, Germany and 4 more countries
Ages 18–99
Biotronik SE & Co. KG · Sites in Australia, Austria, Czechia and 10 more countries
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 1 · Phase 4 8
First in 2004; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 300 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 198 across the 27 interventional studies, 221 across the 18 observational. Of the 39 that completed or were terminated, 13 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Biotronik SE & Co. KG is the lead sponsor of 83 studies on the registry; 6 are open to participants now.
1 of the studies in Heart Failure by Biotronik SE & Co. KG that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07360158Biotronik SE & Co. KGBIO|MASTER.CorSky Family Post-market Study for the CorSky Family of ICDs | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 45 studies in Heart Failure by Biotronik SE & Co. KG, from their registry updates:
This tab as a report to print or save as PDF → With an account.
[Plain language]: Heart failure (HF) patients often experience irregular heartbeats, known as arrhythmias. Atrial fibrillation (AF) is common among HF patients and can worsen their condition, leading to strokes and higher death rates. Most of what we know about arrhythmias in HF comes from patients with devices like ICDs or CRTs, which help manage heart rhythms. However, this study focuses on HF patients who don't qualify for these devices.
Researchers use the BIOMONITOR IV, a device that tracks heart activity remotely over a long period. The goal is to understand how often arrhythmias occur in these patients and to develop a predictive algorithm for worsening HF (WHF). This algorithm could help doctors intervene early and improve treatment, reducing hospital visits and deaths related to WHF.
To make the BIOMONITOR IV more effective for HF management, its firmware is updated to collect additional data, such as fluid levels, breathing rate, and body position. These factors may be important for predicting WHF events.
This study aims to collect clinical data with regard to the two main study objectives:
- Objective arrhythmia: Assess the incidence of arrhythmias and the contribution of the BIOMONITOR to arrhythmia diagnosis and subsequent treatment.
- Objective heart failure events: Collect data from BIOMONITOR sensors and relate them to the heart failure status for development of a predictive algorithm for worsening HF.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least one documented admission with a primary diagnosis of worsening heart failure within last 12 months prior to enrollment;
OR Unscheduled outpatient visit with increase of oral loop diuretics (more than 2-fold) or IV diuretic or ultrafiltration therapy for acute WHF within last 6 months prior to enrollment;
OR elevated NT-proBNP/BNP values within last 3 months prior to enrollment i.e.:
If >50% --> Patients in SR: >450 / >150 pg/ml; Patients with AF present: >900 / >300 pg/ml
If LVEF \<50% --> Patients in SR: >900 / >300 pg/ml; Patients with AF present: >1800 / >450 pg/ml
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All study participants receive the investigational device
Device: BIOMONITOR IV with study software
Participants are inserted with a BIOMONITOR IV which is then turned into the investigational device by replacing the firmware with the study software.
Heart failure events confirmed by WHF Adjudication Committee
* Heart failure hospitalization * Worsening heart failure event without hospitalization
Time frame: Whole study conduct (approx. 3.5 years)
Arrhythmias and subsequent therapeutic interventions
* Incidence of new diagnoses of arrhythmias, by type and therapeutic consequences * Percentage of patients for which the BIOMONITOR contributed to newly diagnosed arrhythmias * Percentage of patients for which the BIOMONITOR contributed to the decision to initiate an arrhythmia therapy
Time frame: Whole study conduct (approx. 3.5 years)
Plan to share: Yes — Anonymized data may be shared with qualified healthcare practitioners or academic researchers upon request and with permission of BIOTRONIK. Requests shall be sent to the Clinical Research Department of BIOTRONIK.
Time frame: To be specified
Access criteria: See above
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Dec 2028, 40 months after the start.
Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 40 months is above that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.